
A study investigated neoadjuvant immunotherapy in patients with locally advanced but resectable head and neck squamous cell carcinoma (HNSCC). Patients received preoperative durvalumab (D) with or without tremelimumab (T), followed by postoperative (chemo)radiotherapy and 1-year D treatment. Of the 48 enrolled patients, 45 underwent surgery as per protocol. D±T showed a favourable safety profile and did not delay surgery. Patients treated with D+T had significantly better distant recurrence-free survival (DRFS) than those receiving D monotherapy. AI-powered analysis revealed immune-inflamed tumour microenvironments with D+T, while high-dimensional profiling showed T-cell subset expansion and activation. These findings suggest potential benefits of preoperative D±T in resectable HNSCC, highlighting distinct immune responses induced by each regimen.
Like
Save
Share